Norovirus Testing: How Rapid PCR Can Support Gastroenteritis (Stomach/Vomiting Bug) Diagnosis.

norovirus stomach vomiting bug

Sudden vomiting. Watery diarrhoea. Abdominal cramps. Nausea.

When several patients develop these symptoms within a short period, norovirus may quickly become one of the pathogens under investigation.

Norovirus is highly contagious and is an important cause of acute gastroenteritis worldwide. Several infectious and non-infectious conditions can cause vomiting and diarrhoea, meaning laboratory confirmation can be valuable when clinicians or infection-control teams need to establish what is circulating.

The Bosch Vivalytic Norovirus test uses qualitative real-time PCR to detect Norovirus genogroup I and genogroup II from soft or liquid stool samples, with results available in approximately 60 minutes.

What Is Norovirus?

what is norovirus

Noroviruses are a group of viruses capable of causing acute gastroenteritis.

The illness typically involves symptoms such as:

  • vomiting,
  • diarrhoea,
  • nausea and
  • abdominal discomfort.

For many people, the illness is relatively short-lived.

However, the consequences can become more significant in vulnerable populations and in environments where many people live or receive care in close proximity.

Bosch highlights this concern in its official Vivalytic Norovirus test information, noting that noroviruses are highly contagious and can pose particular problems for healthcare facilities caring for vulnerable patients.

This makes norovirus both a clinical diagnostic issue and an infection-control issue.

Why Can Norovirus Cause Outbreaks So Easily?

Norovirus spreads efficiently.

Once introduced into an environment such as a hospital ward, nursing facility, school or other communal setting, multiple people can potentially become ill within a relatively short period.

Laboratory testing may help infection-control teams distinguish norovirus from other possible causes of gastrointestinal illness and make more informed decisions about containment measures.

Norovirus Is Relevant Across Africa

Norovirus is not restricted to any particular region of the world.

Available African research indicates that it contributes substantially to acute gastroenteritis across the continent.

A 2022 systematic review and meta-analysis examined 21 African studies involving symptomatic patients who had been tested using molecular diagnostic methods.

The pooled prevalence of norovirus was 20.2%.

The analysis also found that genogroup II accounted for the majority of identified noroviruses, with GII.4 the most frequently reported genotype.

However, the findings varied substantially between countries and studies.

  • It means a pooled African estimate should not be interpreted as the expected prevalence within an individual hospital, city or country.

Instead, the research reinforces another point: that local laboratory surveillance matters.

Why Can’t Norovirus Be Diagnosed From Symptoms Alone?

While Norovirus can produce a recognisable clinical picture, vomiting and diarrhoea cannot.

Other viral pathogens can cause similar symptoms, and so can bacterial pathogens.

This creates a familiar laboratory medicine problem: the clinical syndrome may tell us where to look, but not necessarily which pathogen is responsible.

A molecular diagnostic test can provide additional information by looking directly for viral genetic material.

That is particularly useful during suspected outbreaks, where distinguishing one infectious agent from another can help shape the response.

What Role Does PCR Play in Norovirus Testing?

PCR (polymerase chain reaction) is a molecular technique capable of detecting specific genetic targets associated with a pathogen.

Norovirus is an RNA virus, so molecular diagnostic workflows generally involve converting viral RNA into DNA before amplification.

The test looks for specific genetic sequences associated with norovirus.

For laboratories, PCR offers several advantages:

  • it can be highly sensitive;
  • it can provide results relatively quickly;
  • and it can differentiate genetic targets that would be difficult to identify through clinical assessment alone.

However, PCR results still require appropriate interpretation.

As with other gastrointestinal pathogens, laboratory findings should be considered alongside symptoms, epidemiological circumstances and applicable clinical or public-health guidance.

What Are Norovirus Genogroups I and II?

Noroviruses are genetically diverse. and are divided into different genetic groups known as genogroups.

For human disease, genogroups I and II are particularly important.

This is why the Bosch Vivalytic Norovirus assay is designed to detect:

  • Norovirus genogroup I (GI)
  • Norovirus genogroup II (GII).

The distinction is useful because GII viruses (particularly GII.4 variants) have frequently been associated with human outbreaks and have been prominent in African studies.

A 2022 African systematic review found genogroup II viruses accounted for 89.5% of genogrouped norovirus detections within the included studies.

Again, this does not mean every outbreak will involve GII.

It only demonstrates why a diagnostic assay covering both GI and GII is clinically relevant.

How Does the Vivalytic Norovirus PCR Test Work?

How Does the Vivalytic Norovirus PCR Test Work?

The Vivalytic Norovirus test uses qualitative real-time PCR to detect Norovirus genogroup I and II.

According to the Bosch Vivalytic portfolio, it uses soft or liquid stool samples and provides a result in approximately 60 minutes.

SpecificationVivalytic Norovirus
Detectable PathogenNorovirus genogroup I / II
Detection MethodQualitative real-time PCR
Sample MaterialSoft or liquid stool
Time-to-ResultApprox. 60 minutes
Field of ApplicationSymptomatic patients
Intended SettingProfessional and laboratory use
Sample Volume300 μL per test
Transport Medium2 ml eNAT® (Copan) with regular FLOQSwabs®

Bosch describes the assay as a rapid molecular test intended to support laboratory testing and outbreak containment. The manufacturer also states that only a few steps are required between sample and result and that no additional laboratory equipment is required for the assay workflow.

Healthcare professionals can review the official Bosch Vivalytic Norovirus test information.

What Happens Inside the Vivalytic Workflow?

Molecular testing normally requires several laboratory processes.

These can include:

  • sample preparation,
  • nucleic-acid extraction,
  • amplification
  • and detection.

One of the central characteristics of the Vivalytic platform is that these processes are integrated into an automated cartridge-based workflow.

For a laboratory considering molecular diagnostics, that can be important, as the relevant comparison may not simply be:

60-minute Vivalytic assay versus another 60-minute assay.

The more useful comparison may become:

What staff time, equipment, infrastructure and manual processing are required to get from specimen to result?

This is especially important in laboratories that do not already operate extensive molecular diagnostic infrastructure.

What Could an Approximately 60-Minute Result Mean During an Outbreak?

Imagine several patients on a hospital ward developing sudden vomiting and diarrhoea.

The infection-control team may need to determine whether there is a common infectious cause.

If samples need to be transported to another laboratory, results may not be available immediately.

That delay potentially leaves healthcare teams making decisions based largely on clinical and epidemiological suspicion.

  • A local molecular result available in approximately 60 minutes could potentially provide useful pathogen information earlier in that process.

The important phrase, however, is: potentially support.

A positive norovirus PCR result does not control an outbreak by itself.

Effective response may still require patient isolation or cohorting, appropriate environmental cleaning, hand hygiene, staff-management procedures, surveillance and other measures according to local infection-control guidance.

Rapid diagnostics provide information.

The healthcare system determines how effectively that information is used.

Norovirus or Multiplex Gastrointestinal PCR?

Bosch Vivalytic offers both a single-target Norovirus assay and a multiplex gastrointestinal assay covering:

  • Norovirus genogroup I/II
  • Rotavirus Type A
  • Clostridioides difficile tcdA/tcdB.

The combined Vivalytic Noro-, Rotavirus, C. diff test also uses qualitative real-time PCR and is designed to provide results in approximately 60 minutes.

One Gastrointestinal Test Within a Much Wider Platform

happy doctor

The broader value proposition of Vivalytic is that gastrointestinal testing is only one application area.

Bosch’s current Vivalytic test portfolio includes assays covering:

  • Gastrointestinal infections: including Norovirus, C. difficile and a combined Norovirus/Rotavirus/C. difficile assay;
  • Sexually transmitted infections;

This is commercially relevant for laboratories.

The business case for purchasing a molecular analyser may not depend on whether the organisation performs enough norovirus tests alone.

A more useful calculation might be:

How many molecular diagnostic requirements could this device potentially address across our hospital or laboratory?

That broader question can substantially change an equipment assessment.

Questions Laboratory Managers Should Consider

Before introducing rapid norovirus PCR testing, healthcare organisations should consider:

  • How frequently do we investigate acute gastroenteritis?
  • How often do we experience suspected gastrointestinal outbreaks?
  • Which patient groups would be tested?
  • Are specimens currently processed locally or referred elsewhere?
  • What is our current sample-to-result turnaround time?
  • Would faster pathogen identification change infection-control decisions?
  • Do we currently differentiate norovirus from other causes of gastroenteritis?
  • Would a targeted norovirus test or multiplex gastrointestinal assay better suit our patient population?
  • What molecular diagnostic infrastructure do we already have?
  • What staff training would be required?
  • How reliably can cartridges and compatible collection materials be supplied?
  • What technical and after-sales support is available?
  • Which additional Vivalytic assays could be used within our organisation?

These are more important questions than simply comparing analyser specifications.

The objective is to determine whether the technology fits the clinical workload and diagnostic requirements of the healthcare organisation.

Is Your Laboratory Considering Rapid Norovirus PCR Testing?

If your hospital, laboratory, clinic or healthcare organisation is reviewing its norovirus testing, gastrointestinal diagnostics or wider molecular diagnostic capabilities, MediDiagAfrica can provide further information about the Bosch Vivalytic platform and Vivalytic Norovirus assay.

The conversation can begin with your existing workflow:

  • How do you currently investigate suspected norovirus?
  • How long does it take to receive laboratory confirmation?
  • Are specimens processed locally or referred elsewhere?
  • Would targeted or multiplex gastrointestinal PCR better fit your diagnostic requirements?

From there, you can:

Request information about the Vivalytic Norovirus test

Request a Vivalytic demonstration

Discuss your laboratory’s gastrointestinal testing requirements

Enquire about Vivalytic availability in your country

Bosch advises that individual Vivalytic products may not be available in every market, so regional availability should be confirmed before procurement.

This article is intended for healthcare and laboratory professionals and provides general diagnostic and product information. It should not replace clinical guidelines, professional medical judgement, infection-control procedures, local laboratory protocols or applicable regulatory requirements.


Leave a Reply